Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1955 1
2006 1
2007 2
2008 1
2009 1
2011 1
2013 1
2015 1
2016 1
2017 3
2019 3
2021 3
2022 3
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Macé S, Corzo KP, Campana F, Le-Guennec S, Dubin F, Anderson KC; ICARIA-MM study group. Attal M, et al. Among authors: dubin f. Lancet. 2019 Dec 7;394(10214):2096-2107. doi: 10.1016/S0140-6736(19)32556-5. Epub 2019 Nov 14. Lancet. 2019. PMID: 31735560 Clinical Trial.
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study.
Richardson PG, Perrot A, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Malinge L, Dubin F, van de Velde H, Anderson KC. Richardson PG, et al. Among authors: dubin f. Lancet Oncol. 2022 Mar;23(3):416-427. doi: 10.1016/S1470-2045(22)00019-5. Epub 2022 Feb 10. Lancet Oncol. 2022. PMID: 35151415 Clinical Trial.
Extended Bose-Hubbard model with dipolar excitons.
Lagoin C, Bhattacharya U, Grass T, Chhajlany RW, Salamon T, Baldwin K, Pfeiffer L, Lewenstein M, Holzmann M, Dubin F. Lagoin C, et al. Among authors: dubin f. Nature. 2022 Sep;609(7927):485-489. doi: 10.1038/s41586-022-05123-z. Epub 2022 Sep 14. Nature. 2022. PMID: 36104551
Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis.
Richardson PG, Perrot A, Miguel JS, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang SY, Minarik J, Cavo M, Prince HM, Macé S, Zhang R, Dubin F, Morisse MC, Anderson KC. Richardson PG, et al. Among authors: dubin f. Haematologica. 2024 Feb 1. doi: 10.3324/haematol.2023.284325. Online ahead of print. Haematologica. 2024. PMID: 38299578 Free article.
Bose-Einstein condensation and indirect excitons: a review.
Combescot M, Combescot R, Dubin F. Combescot M, et al. Among authors: dubin f. Rep Prog Phys. 2017 Jun;80(6):066501. doi: 10.1088/1361-6633/aa50e3. Epub 2017 Mar 29. Rep Prog Phys. 2017. PMID: 28355164
Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma.
Usmani SZ, Karanes C, Bensinger WI, D'Souza A, Raje N, Tuchman SA, Sborov D, Laubach JP, Bianchi G, Kanagavel D, Saleem R, Dubin F, Campana F, Richardson PG. Usmani SZ, et al. Among authors: dubin f. Leukemia. 2021 Dec;35(12):3526-3533. doi: 10.1038/s41375-021-01262-w. Epub 2021 May 28. Leukemia. 2021. PMID: 34050260 Free PMC article. Clinical Trial.
Superlattice Quantum Solid of Dipolar Excitons.
Lagoin C, Baldwin K, Pfeiffer L, Dubin F. Lagoin C, et al. Among authors: dubin f. Phys Rev Lett. 2024 Apr 26;132(17):176001. doi: 10.1103/PhysRevLett.132.176001. Phys Rev Lett. 2024. PMID: 38728707
24 results